Arvind Suresh's Avatar

Arvind Suresh

@arvindsuresh1.bsky.social

IM PGY-2 @UCSF | @GeiselMed '23 | @Dartmouth '19 | Aspiring hematologist/oncologist interested in myeloma #MMsm, cell therapy, med ed & health equity | he/him

52 Followers  |  151 Following  |  4 Posts  |  Joined: 17.11.2024  |  1.5144

Latest posts by arvindsuresh1.bsky.social on Bluesky

@ajaichari.bsky.social @drkomanduri.bsky.social

18.10.2025 02:34 β€” πŸ‘ 0    πŸ” 0    πŸ’¬ 0    πŸ“Œ 0
Our strategy to address relapse after BCMA CAR T-cell therapy depends on whether a patient has rapid aggressive relapse (i.e., extramedullary disease, plasma cell leukemia, or rapidly rising myeloma markers or disease burden) or biochemical/clinical relapse without aggressive features. For all patients, talquetamab or another GPRC5D bispecific is a preferred approach. For rapid aggressive relapse, high dose cytotoxic chemotherapy or salvage autologous stem cell transplant may also be considered. For other relapses, a retrial of BCMA targeted therapy or various proteasome inhibitor and immunomodulatory drug combinations can be considered. The rapidly changing landscape of available drugs means that several novel approaches or clinical trials may also be available for patients.

Our strategy to address relapse after BCMA CAR T-cell therapy depends on whether a patient has rapid aggressive relapse (i.e., extramedullary disease, plasma cell leukemia, or rapidly rising myeloma markers or disease burden) or biochemical/clinical relapse without aggressive features. For all patients, talquetamab or another GPRC5D bispecific is a preferred approach. For rapid aggressive relapse, high dose cytotoxic chemotherapy or salvage autologous stem cell transplant may also be considered. For other relapses, a retrial of BCMA targeted therapy or various proteasome inhibitor and immunomodulatory drug combinations can be considered. The rapidly changing landscape of available drugs means that several novel approaches or clinical trials may also be available for patients.

How should we choose optimal salvage treatments following BCMA-directed CAR-T therapy in multiple myeloma?

Check out our review article out today summarizing recent studies and our approach to therapy sequencing from our team at @ucsfcancer.bsky.social #MMsm #myeloma

dx.doi.org/10.1080/1750...

18.10.2025 02:29 β€” πŸ‘ 1    πŸ” 1    πŸ’¬ 1    πŸ“Œ 0

I enjoyed working with colleagues and mentors at Dartmouth to create and lead these workshops for medical students and faculty to develop skills in addressing microaggressions and bias in their roles as health care professionals, educators, and leaders. Learn more belowπŸ‘‡ @aamctoday.bsky.social

28.04.2025 04:06 β€” πŸ‘ 1    πŸ” 2    πŸ’¬ 0    πŸ“Œ 0
Post image

At #Tandem25: @drkomanduri.bsky.social
accepts the ASTCT advocacy award. Congratulations Dr. Komanduri, we commend you for your dedication to advancing our field!

15.02.2025 00:31 β€” πŸ‘ 13    πŸ” 4    πŸ’¬ 1    πŸ“Œ 0
Post image

Grateful to Clinical Lymphoma, Myeloma & Leukemia, co-authors, and @ash-hematology.bsky.social for the opportunity to share this research on targeted neurocognitive testing after anti-CD19 and anti-BCMA #CART cell therapy. #lymsm #mmsm

clinical-lymphoma-myeloma-leukemia.com/article/S215...

26.12.2024 20:03 β€” πŸ‘ 0    πŸ” 0    πŸ’¬ 1    πŸ“Œ 0

@arvindsuresh1 is following 20 prominent accounts